CMS Granted NTAP Status for Spinal Bone Graft
Hospitals may now receive supplemental Medicare reimbursement for using the PearlMatrix P-15 bone graft technology.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should Medicare provide extra payments to hospitals for adopting expensive new medical technologies?
The Centers for Medicare and Medicaid Services granted New Technology Add-on Payment (NTAP) status to the PearlMatrix P-15 Peptide Enhanced Bone Graft. This status provides hospitals with supplemental reimbursement for using the product in Medicare patients undergoing lumbar spinal fusion.
Why it matters
The designation lowers financial barriers to adopting novel spinal technologies by offsetting up to 65% of additional costs. This could accelerate the clinical adoption of advanced bone grafts for both hospital systems and their private-market counterparts.
The NTAP program provides up to 65% reimbursement of the additional costs for the technology compared to standard hospital payments. This decision follows a pivotal study where fusion rates at six months were more than double those achieved with local autograft.
The players
Centers for Medicare and Medicaid Services
The federal agency that administers the Medicare program and sets reimbursement policies for hospitals.
Cerapedics
A medical device company based in Westminster, Colorado, that specializes in bone graft technology for spinal and orthopedic procedures.
The details
PearlMatrix acts as a Class III drug-device combination that uses a 15-amino-acid peptide bound to calcium phosphate to accelerate bone cell growth. Hospitals using the graft for intervertebral body fusion must pair it with an interbody fusion device and internal fixation systems. By offsetting these costs, the NTAP status aims to increase access for high-risk patients, who accounted for 60% of the subjects in the pivotal study.
Timeline
October 1, 2026: PearlMatrix NTAP status became effective.
Market Landscape
The CMS New Technology Add-on Payment program is designed to facilitate the rapid adoption of breakthrough technologies by addressing the financial gap between innovation costs and standard diagnostic-related group payments. This status marks a critical regulatory milestone that often serves as a signal for private insurers to evaluate similar coverage updates.
Hospital administrators and surgeons should update billing protocols to capture the new NTAP supplemental reimbursement for eligible Medicare claims. Operators should also monitor if private payers adopt similar coverage incentives for the P-15 technology in the coming fiscal cycle.
The takeaway
The CMS designation validates the clinical utility of P-15 peptide-enhanced grafts for high-risk spinal fusion procedures. Operators should audit their current bone graft procurement costs against the new Medicare reimbursement thresholds to optimize margin performance.
Further reading
For more on industry regulatory trends, see the Healthcare section.
More information
For detailed product specifications and clinical instructions, visit the Cerapedics website.
Source note: This article includes information reported by CacheValleyDaily.
Live Poll
Should Medicare provide extra payments to hospitals for adopting expensive new medical technologies?
